Published in AIDS on June 01, 1994
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev (1998) 9.76
Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol (1996) 2.19
Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother (1998) 2.15
Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother (1997) 1.54
Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol (1995) 1.44
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother (1995) 1.35
Azole resistance in Candida. Eur J Clin Microbiol Infect Dis (1997) 1.23
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother (1999) 1.15
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol (1997) 1.11
Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrob Agents Chemother (1996) 0.99
In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother (1995) 0.99
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob Agents Chemother (1996) 0.96
Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: pharmacological and mycological factors. Antimicrob Agents Chemother (1996) 0.86
NADPH cytochrome P-450 oxidoreductase and susceptibility to ketoconazole. Antimicrob Agents Chemother (1998) 0.85
T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations. Antimicrob Agents Chemother (1997) 0.85
Pharmacokinetics of two multiple-dosing regimens of D0870 in human immunodeficiency virus-positive patients: a phase I study. Antimicrob Agents Chemother (1998) 0.75
In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp. Antimicrob Agents Chemother (1996) 0.75
Fluconazole-resistant oral candidosis in HIV-infected patients. AIDS (1995) 0.75
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
The rectal biopsy appearances in Salmonella colitis. Histopathology (1978) 4.53
Campylobacter colitis. Br Med J (1979) 3.89
Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect (2000) 3.72
A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med (1994) 3.72
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Failure of chloroquine and proguanil prophylaxis in travellers to Kenya. Lancet (1991) 3.03
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Fluconazole resistant candida in AIDS. J Infect (1991) 2.97
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 2.79
Diphtheria in the Manchester area 1967-1971. Lancet (1974) 2.70
Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (2007) 2.49
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
Abdominal tuberculosis in Britain. Practitioner (1976) 2.41
Contemporary gastroenteritis of infancy: clinical features and prehospital management. Br Med J (Clin Res Ed) (1984) 2.25
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect (1993) 2.10
Colonic involvement in salmonellosis. Lancet (1976) 2.06
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
Haemolytic crisis produced by nalidixic acid. Lancet (1970) 1.90
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J (2010) 1.87
Micro-organisms in gastroenteritis. Arch Dis Child (1984) 1.86
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Invasive illness with Salmonella virchow infection. Br Med J (1974) 1.83
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (1994) 1.82
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett (1995) 1.66
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. J Clin Microbiol (1996) 1.65
Diphtheria--the continuing hazard. Arch Dis Child (1988) 1.64
Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2002) 1.61
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Invasive infection due to penicillium species other than P. marneffei. J Infect (2002) 1.58
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis (2008) 1.57
Multiple drug reactions in a patient with AIDS. Lancet (1989) 1.55
Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim (2003) 1.53
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother (1993) 1.51
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Cross-infection in infantile gastroenteritis. Arch Dis Child (1971) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
A clinicopathological study of acute colitis: the dilemma of transient colitis syndrome. Scand J Gastroenterol (1982) 1.47
Dipylidium caninum in an infant. Eur J Pediatr (1992) 1.47
The influenza epidemic. Br Med J (1970) 1.45
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Arsenic poisoning in the Ganges delta. Nature (1999) 1.44
Aspergillus fungemia: report of two cases and review. Clin Infect Dis (1995) 1.42
Whooping cough--a study of severity in hospital cases. Arch Dis Child (1981) 1.42
New and emerging treatments for fungal infections. J Antimicrob Chemother (2008) 1.42
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis (1991) 1.40
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Endemic mycoses: a treatment update. J Antimicrob Chemother (1999) 1.39
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
Arsenic in groundwater in six districts of West Bengal, India. Environ Geochem Health (1996) 1.37
CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res (2004) 1.36
The declining incidence of infantile hypernatremic dehydration in Great Britain. Am J Dis Child (1979) 1.35
Microsporidiosis in a British patient with AIDS. J Clin Pathol (1988) 1.35
Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect (2009) 1.32
Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother (1997) 1.32
Administering amphotericin B--a practical approach. J Antimicrob Chemother (1994) 1.32
Aspergillus wound infection following laparostomy. J Infect (1996) 1.31
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2008) 1.31
Clostridium difficile and its cytotoxin in infants admitted to hospital with infectious gastroenteritis. Br Med J (Clin Res Ed) (1984) 1.30
Adenovirus infections in human immunodeficiency virus-positive patients: clinical features and molecular epidemiology. J Infect Dis (1995) 1.30
Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect (1999) 1.29
Diphtheria carriers in Manchester: simultaneous infection with toxigenic and non-toxigenic mitis strains. Lancet (1980) 1.29
Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1987) 1.28
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
Molecular genetics in Aspergillus fumigatus. Curr Opin Microbiol (2000) 1.27
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol (2010) 1.26
Open study of ciprofloxacin in enteric fever. J Antimicrob Chemother (1989) 1.26
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother (2006) 1.26
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect (1995) 1.23
Toxic dilatation of the colon in salmonella colitis and inflammatory bowel disease. Br J Surg (1979) 1.22
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother (1998) 1.19
Post-operative aspergillosis. Clin Microbiol Infect (2006) 1.19
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy (2009) 1.18
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med (1995) 1.17
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun (1996) 1.14
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother (1998) 1.14
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol (1997) 1.13
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother (1999) 1.12
Pseudomembranous colitis in a 5-week-old infant. Br Med J (Clin Res Ed) (1982) 1.12
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol (1997) 1.11
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother (2001) 1.10
Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol (1996) 1.10
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect (2001) 1.09
The dilemma of partially treated bacterial meningitis. Scand J Infect Dis (1976) 1.09
When to use fluconazole. Lancet (1995) 1.07
Skin rash after triple vaccine. Arch Dis Child (1987) 1.07
Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med (1990) 1.07
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother (2001) 1.06
Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis (1990) 1.06